Tempus AI: Price Rally Thanks to new Algorithm in AI Diagnostics
Reading Time: 3 minutes
Product revolution: A novel pan-cancer HRD RNA algorithm clinically demonstrates its superiority and significantly reduces mortality risk in cancer patients. Analyst tailwind: TD Cowen upgrades the stock to Buy after a strong price decline, seeing enormous scaling potential in the data/insights segment. Volume explosion : The combination of strong quarterly results and a massive price jump of +13% is currently attracting institutional buyers in large numbers. A breakthrough in AI diagnostics as well as strong quarterly...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
